S Del Prato, DW Erkelens, M Leutenegger - Acta Diabetologica, 2003 - Springer Abstract Six-month efficacy of benfluorex (Mediator) (150–450 mg/day) was assessed in a
double-blind multicen- ter study vs. placebo or metformin hydrochloride (850–2550 mg/day).
After a 2-month run-in period of strict dieting, 722 type 2 diabetic patients were ... Cited by 13 - Related articles - BL Direct - All 3 versions
M Caüzac, C Kohl, J Girard, JP Pégorier - Biochemical pharmacology, 2005 - Elsevier S-15261 is a new oral anti-hyperglycemic agent that increases insulin sensitivity in various
insulin-resistant animal models. The aim of this study was to determine the short- and long-term
effects of S-15261 and its metabolites (S–15511 and Y-415) on fatty acid and glucose ... Cited by 6 - Related articles - All 3 versions
P Moulin, M Andre, H Alawi, LC dos Santos, AK Khalid, … - Diabetes care, 2006 - ncbi.nlm.nih.gov OBJECTIVE: The aim of this study was to demonstrate the superiority of benfluorex over placebo
as an add-on therapy in type 2 diabetic patients in whom diabetes is insufficiently controlled
by sulfonylurea monotherapy and who have a limitation for the use of metformin. ... Cited by 3 - Related articles - BL Direct - All 3 versions
P Moulin, M Andre, H Alawi, LC dos Santos, AK … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—Both groups were similar at baseline in the intention-to-treat population. A1C significantly
decreased with benfluorex from 8.34 ± 0.83 to 7.52 ± 1.04% (P < 0.001) and tended to increase
with placebo from 8.33 ± 0.87 to 8.52 ± 1.36% (NS), resulting in a mean adjusted ... Cited by 1 - Related articles - All 2 versions
- ►pharm.or.jp [PDF] A Yano, M Kubota, K Iguchi, S Usui, K Hirano - Biological & pharmaceutical …, 2006 - J-STAGE Three biguanides, phenformin, buformin, and metformin, were first used clinically for diabetes
mellitus in the 1950s. Since phenformin was found to have a lethal side effect, lac- tic
acidosis, in the late of 1970s, 1) its usage decreased rapidly in many countries and was ... Related articles - BL Direct - All 7 versions
P Moulin, M André, H Alawi, LC Dos Santos, AK … - Diabetes and Metabolism, 2009 - Elsevier Between W18 and the end of treatment, HbA 1c decreased in the PB group from 8.53 ± 1.37%
to 7.49 ± 1.04% (P < 0.001) and remained stable in the BB group from 7.52 ± 1.07% to 7.53 ±
1.14% (NS). In the PB group, parameters of glycemic control showed improvements from ... Related articles - All 2 versions
- ►sdu.edu.tr [PDF] DVEBCV UYGULAMALI, SDELİFVE FİBROBLAST, DM … - edergi.sdu.edu.tr Özet: Bu çalışma streptozotosin diyabetik ve benfluoreks–C vitamini tedavisi uygulanmış diyabetli
derinin dermisindeki elastik lif ve fibroblastlarda meydana gelen değişimleri incelemektedir.
Işık ve elektron mikroskobu incelemelerinde diyabet grubunda dermis kalınlaşması, ... Related articles - View as HTML - All 2 versions
ПК Телушкин, АД Ноздрачев, ПП Потапов, НБ … - Проблемы …, 2006 - elibrary.ru У крыс вызывали гипогликемическую кому путем введения 40 ЕДинсулина на 1 кг массы
тела. У животных, перенесших 7 гипогликемических ком с интервалом 2 сут и забитых во
время последней из серии ком, обнаружено увеличение содержания свободных ... Related articles
